… company was founded in 2012, our mission has been to help people living with rare diseases that currently have no treatment options. This remains an important focus of our company … Read more about our Founding story . Patient-focused drug development Patient-focused drug development In order to …
… ways, including via the Whistleblower Hotline which is operated by a third party SpeakUp and always available. The … confidential communication, and also allows for (optional) anonymous reporting. Report submitted to the … who will decide on further steps of investigation, as appropriate. Whistleblower Hotline reports may be made via …
… with a rare genetic disorder, with the objective to develop RNA therapies for rare diseases. Prior to founding … background in RNA modulation and orphan drug discovery and development and is currently in charge of our R&D. Gerard has … has led in the development of structure-guided methods for optimizing chemically modified oligonucleotides for …
At ProQR, we are dedicated to improving the lives of patients and families affected by rare and common disorders using Axiomer, our innovative RNA editing platform technology.
At ProQR we take care to give all applicants a good experience and value their time and interest in applying to become a ProQRian. On this page, you can find an overview of what you can expect throughout the recruitment process, until your first onboarding week.
… sepofarsen captain. The work of her department, aimed at developing a novel drug for Leber congenital amaurosis 10 … in Venezuela and now heading ProQR’s LCA research and development team in Leiden (The Netherlands), has multiple reasons for being optimistic. Obviously, as a biotech scientist looking for a …
There are currently around 160 people working at ProQR, but that wasn’t always the case. When Hee Lam Chan joined in 2013, she was only employee number six. As a result, she has seen the company grow and develop.
… long before that Gerard Platenburg was involved in the development of RNA therapies. Even so, after decades of … RNA therapies.” But what about gene therapy, isn’t that an option? “There are several reasons to choose RNA therapy over … Can we learn more about our molecules, and does it help to optimize our protocols? Those are just some of the questions …
